Online first
Case report
Published online: 2024-05-24

open access

Page views 83
Article views/downloads 61
Get Citation

Connect on Social Media

Connect on Social Media

Long-term survival and remarkably durable treatment response in a case of inoperable fibrolamellar carcinoma of the liver — a comprehensive analysis of an 8-year chemotherapeutic journey

Bartosz T. Wojewoda1, Magdalena Ulatowska-Białas2, Paweł M. Potocki3

Abstract

Hepatocellular carcinoma is the most common primary malignancy of the liver. The fibrolamellar subtype of hepatocellular carcinoma (FLHCC) is a rare liver malignancy constituting ~0.5% of liver cancers. FLHCC can be distinguished by its lack of specific risk factors and unique molecular profile. This case study aims to present an 8-year medical history of a 32-year-old patient with unresectable FLHCC and his outstanding response to systemic therapy. The patient was referred to the liver surgery center due to suspicion of liver cancer based on radiological findings. The tumor turned out to be inoperable and a surgical biopsy was performed. Histopathology confirmed fibrolamellar carcinoma. Six transarterial chemoembolization procedures with doxorubicin-eluting microspheres were performed, which resulted in disease control. Subsequently, from April 2013 to December 2021, the patient received 11 lines of systemic treatment. Sorafenib resulted in disease control lasting 28 months. Cisplatin did not trigger any response. Systemic doxorubicin provided 6 months of stabilization. The patient did not respond to subsequent lines of capecitabin plus temozolomide, vinorelbine, cyclophosphamide, or 5-fluorouracil plus interferon α2b. The reintroduction of sorafenib resulted in 7 months of disease stabilization, and subsequent regorafenib, used as the 9th line of treatment, led to an objective response lasting 26 months. Later, two more lines of treatment consisting of cabozantinib and paclitaxel were administered and they were not effective. The patient died in December 2021 due to liver failure and hemorrhage. 

FLHCC treatment needs an individual approach. One can hope that in the future, more data on FLHCC management will be available.

Article available in PDF format

View PDF Download PDF file

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
  2. Altekruse SF, Devesa SS, Dickie LA, et al. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag. 2011; 38(4): 201–205.
  3. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1): 6.
  4. EDMONDSON HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956; 91(2): 168–186.
  5. Craig J, Peters R, Edmondson H, et al. Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980; 46(2): 372–379, doi: 10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s.
  6. Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005; 18(11): 1417–1423.
  7. Riggle KM, Turnham R, Scott JD, et al. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. Pediatr Blood Cancer. 2016; 63(7): 1163–1167.
  8. Darcy DG, Chiaroni-Clarke R, Murphy JM, et al. The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients. Oncotarget. 2015; 6(2): 755–770.
  9. Chen X, Lu Y, Shi X, et al. Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma. Front Oncol. 2022; 12: 864106.
  10. Polychronidis G, Feng J, Murtha-Lemekhova A, et al. Factors Influencing Overall Survival for Patients with Fibrolamellar Hepatocellular Carcinoma: Analysis of the Surveillance, Epidemiology, and End Results Database. Int J Gen Med. 2022; 15: 393–406.
  11. Eggert T, McGlynn KA, Duffy A, et al. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterol J. 2013; 1(5): 351–357.
  12. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343(6174): 1010–1014.
  13. Qiu S, Chen R, Hu J, et al. The prognosis of fibrolamellar carcinoma versus conventional hepatocellular carcinoma: a study based on propensity score matching. Scand J Gastroenterol. 2023; 58(11): 1351–1358.
  14. Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer. 2013; 49(12): 2698–2704.
  15. Mafeld S, French J, Tiniakos D, et al. Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection. Cardiovasc Intervent Radiol. 2018; 41(5): 816–820.
  16. Aguado A, Ristagno R, Towbin AJ, et al. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer. 2019; 66(7): e27510.
  17. Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019; 72: 28–36.
  18. Gummadi J, Wang X, Xie C. Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver. J Hepatocell Carcinoma. 2023; 10: 745–752.
  19. Peacock J, Call J, Olivier K. Radiotherapy for Metastatic Fibrolamellar Hepatocellular Carcinoma. Rare Tumors. 2013; 5(3): e28.
  20. Toyota A, Goto M, Miyamoto M, et al. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model. Biochem Biophys Res Commun. 2022; 621: 157–161.
  21. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003; 21(3): 421–427.
  22. Aryan M, Forrister N, Panchani N, et al. A focused review on recent advances in diagnosis and management of fibrolamellar hepatocellular carcinoma. Hepatoma Res. 2022; 8(5): 25.
  23. El Dika I, Mayer RJ, Venook AP, et al. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. Oncologist. 2020; 25(11): 925–e1603.
  24. Abou-Alfa GK, Mayer R, Venook AP, et al. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist. 2020; 25(12): e1837–e1845.
  25. Walz J. FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition (FusionVAC22) [Internet]. https://classic.clinicaltrials.gov/ct2/show/record/NCT05937295.
  26. Yarchoan M. DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma [Internet]. https://clinicaltrials.gov/study/NCT04248569?tab=table.
  27. 27. KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) [Internet]. https://clinicaltrials.gov/study/NCT05603572.
  28. Gottlieb S, O'Grady C, Gliksberg A, et al. Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma. Oncology. 2021; 99(5): 310–317.
  29. O’Neill A. Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma [Internet] https://clinicaltrials.gov/study/NCT04134559.
  30. Gartrell J. ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients [Internet]. https://classic.clinicaltrials.gov/ct2/show/NCT05468359.
  31. Tiao GM. NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery [Internet]. https://clinicaltrials.gov/study/NCT03533582.
  32. 32. Naing A. Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Internet]. https://clinicaltrials.gov/study/NCT02159989.
  33. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009; 10(8): 794–800.
  34. Baretti M. DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) [Internet]. https://classic.clinicaltrials.gov/ct2/show/NCT06027086.
  35. Muramori K, Taguchi S, Taguchi T, et al. High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol. 2011; 33(5): e195–e197.
  36. Dinh TA, Vitucci ECM, Wauthier E, et al. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Sci Rep. 2017; 7: 44653.
  37. O'Neill AF, Church AJ, Perez-Atayde AR, et al. Fibrolamellar carcinoma: An entity all its own. Curr Probl Cancer. 2021; 45(4): 100770.
  38. Kuczynski EA, Lee CR, Man S, et al. Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Res. 2015; 75(12): 2510–2519.
  39. Ikeda A, Aoki K, Kawamura M, et al. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma. Intern Med. 2021; 60(3): 403–407.
  40. European Medicinies Agency. STIVARGA® (regorafenib) 20210712. 2017; 1: 1–25.
  41. Bruix J, Qin S, Merle P, et al. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10064): 56–66.
  42. Lompart J, Sałek-Zań A, Puskulluoglu M, et al. Novel systemic treatment for hepatocellular carcinoma: a step-by-step review of current indications. Nowotwory. Journal of Oncology. 2023; 73(3): 147–153.
  43. Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020; 5(1): 87.
  44. Cheng AL, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20): 1894–1905.
  45. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022; 1(8): EVIDoa2100070.
  46. Vogel A, Martinelli E. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021; 32(6): 801–805.